# VISTIN PHARMA

# VISTIN PHARMA ASA

# FOURTH QUARTER AND PRELIMINARY 2021 RESULTS PUBLISHED 17 FEBRUARY 2022

# HIGHLIGHTS

- Revenue of MNOK 78 compared to MNOK 64 in fourth quarter 2020, a 21% increase. Revenue increase driven by higher sales volume (+29%) and sales prices, partly offset by a significant stronger NOK vs EUR
- Revenue of MNOK 279 in 2021 compared to MNOK 254 in 2020, a growth of 10%. Currency neutral, the revenue growth YoY is approx. 15%
- EBITDA for Pharmaceuticals of MNOK 12.2 in fourth quarter 2021 compared to MNOK 13.9 in fourth quarter 2020 (-13%). EBITDA unfavorably affected by FX, increased raw material prices, record high international freight costs, bonus accrual and higher electricity prices in the quarter compared to last year
- Higher sales prices successfully negotiated with customers in Q4 to reflect increased cost base
- 2021 EBITDA of MNOK 49 versus MNOK 58 in 2020. Net unfavorable FX effect on '21 EBITDA vs '20 is approx. MNOK 7
- All-time high sales volume in 2021; 3 748MT compared to 3 360MT in 2020
- Slightly improved predictability in freight lead time from Asia to Europe. Additional safety stocks of key raw materials will be kept in 1H'22
- Metformin capacity expansion project (MEP) on track and expected to be commercially operational from Q2 2022. Existing line #1 successfully resumed production in second week of February. Approximately 55% of the total investment of MNOK 100 paid as of end December
- Cash balance of MNOK 36 as of 31 December and no interest-bearing debt
- Board proposes to get a power of attorney from AGM in May to pay up to NOK 0.75 per share in dividend for 2021, by end of 2022

# 4TH QUARTER REPORT AND PRELIMINARY FINANCIALS FOR 2021


The financial report as per December 2021 has been prepared according to the IFRS (International Financial Reporting Standard) and follows IAS 34 for interim financial reporting, as do the comparable numbers for 2020.


# FINANCIAL DEVELOPMENT

(Comparative numbers for 2020 in parenthesis)

# REVENUE

Revenue in the quarter of MNOK 78.1 (MNOK 64.4), a 21% increase compared to Q4 2020. The revenue increase was driven by higher sales volume and increased average selling price, partly offset by a significantly stronger NOK vs. EUR.







# Cost of goods sold

Cost of goods sold (COGS) in the quarter ended at MNOK 66.8 (MNOK 51.2). In addition to the increased volume, the main drivers are record high transportation costs, high global raw material prices, increased electricity and water prices compared to last year, partly offset by volume leverage due to the new reactor and increased capacity.

# EARNINGS


Pharmaceuticals achieved an EBITDA of MNOK 12.2 (MNOK 13.9) for the quarter. EBITDA unfavorably affected by bonus accrual of MNOK 4 (MNOK 2.5). Earnings before tax (EBT) ended at MNOK 9.9 (MNOK 11.5). Vistin has successfully negotiated price compensations with customers in Q4 to reflect the significant higher cost base.





# PRODUCTION

The Fikkjebakke plant has been operating at full capacity and with high efficiency and productivity throughout the quarter, except for a 5-day planned maintenance stop in October. The new  $2^{nd}$  reactor which was installed in Q3/Q4'20 has resulted in an increase of almost 2 batches produced per week. The output from the dedicated metformin plant reached a record high production volume of 3 630MT in 2021.



# Other (HQ)

HQ and other Group activities had EBT of negative MNOK 0.7 for the fourth quarter, compared to negative MNOK 0.5 in the same quarter last year. The consolidated EBT for the Group, ended at MNOK 9.2 (MNOK 11.1) in the fourth quarter.

# Financial items

Net finance ended negative with MNOK 0.1 for the fourth quarter 2021, compared to positive of MNOK 0.2 in fourth quarter 2020. Net finance expense in Q4'21 was mainly related to realized and unrealized gains or losses related to customer receivables and currency hedging contracts.

# **CASH FLOW**

YTD net cash flow from operating activities was MNOK 27. Net cash flow from operating activities in same period of 2020, excluding Vistin Trading, was MNOK 45 in 2020.

Net cash flow from investing activities in 2021 was negative MNOK 39 which represents capital expenditure, mainly MEP. Net cash flow from investing activities in the same period last year was negative MNOK 52.

Net cash flow from financing activities YTD was negative MNOK 29.8, driven by dividend pay-out in June. Net cash flow from financing activities in the same period last year was negative MNOK 45.8.

Net decrease in cash and cash equivalents in 2021 amounted to MNOK 41.3. In the same period last year, there was a net decrease in cash and cash equivalents of MNOK 242.6 due to realization of the oil derivative contracts in Energy Trading, which was closed down in Q1'20.

# BALANCE SHEET

# Assets

Vistin Pharma had total assets of MNOK 333 as of 31 December 2021. Cash and cash equivalents amounted to MNOK 36.

The company has a deferred tax asset of MNOK 27.9 (MNOK 35.1). Based on the financial

forecasts for the company the deferred tax asset is expected to be fully utilized, and thus the full amount has been included as carrying value in the balance sheet.

# Equity

Equity by the end of December was MNOK 276. This equals an equity ratio of 83%.

# Liabilities

The company had no interest-bearing debt as of end December 2021. MNOK 1.4 (MNOK 1.9) in obligations related to lease contracts are recognized in the balance sheet according to IFRS 16.

# **OPERATIONAL STATUS**

# MARKET

It is a strong underlying global demand in the metformin market. The market is expected to grow by 5-6% annually in the foreseeable future. Metformin is the standard first-line treatment of Type 2 Diabetes, which contribute to 90% of the population suffering from diabetes. The majority of Vistin Pharma's key customers are pharmaceutical companies that sell new and innovative metformin products to the end users. product demand will therefore The be dependent on the performance of these products in the market. Key drivers for future growth are the number of diabetes patients diagnosed and treated with metformin containing products, continued growth in sales volume from existing multinational customers, as well as adding new customers to its portfolio. The company is currently experiencing strong demand for its products.

# **STRATEGY / MEP**

In April 2020 Vistin announced that the Board of Directors had approved a Metformin Capacity Expansion Project (MEP). The objective is to build a 2nd parallel production line and establish a total capacity of approx. 7000MT metformin HCl annually (+ 3500MT). The estimated CAPEX is MNOK 100, whereof approx. 55% has been paid as of 31 December. Business development activities to acquire new accounts and to secure increased volumes from existing customers to fill the additional MEP capacity are ongoing. In relation to the MEP installation, production was closed down first week of January, as planned. Line 1 successfully resumed normal production second week of February. The first commercial batch from Line 2 is expected to be shipped out of Plant in Q2. Implementation of MEP is leading to low volumes available for sale in Q1'22 and an untraditionally weak result in the period is expected. The financial results is expected to improve from Q2'22, and accelerate from 2H with leverage from the new capacity. The 2022 production target is 5000 MT.

Vistin expects significant increased working capital requirements to support the volume ramp-up. In addition, Vistin has an ambitious CAPEX plan in 2022 to support the volume growth and future production productivity. Based on this a credit facility has been secured with Nordea.

## **RESEARCH AND DEVELOPMENT (R&D)**

Vistin has positioned itself as a premium supplier. To strengthen the position in the market, Vistin is committed to invest in process and product quality development and take advantage of Best Available Techniques (BAT) in its production environment. Vistin has a separate department consisting of four highly competent engineers who are dedicated to work with process, productivity, and quality improvements.

# THE COVID-19 PANDEMIC

The demand in the market for metformin is still high and is not affected by the corona epidemic. The delivery situation of raw materials from China has slightly improved. However, there are still uncertainties around delivery lead time and based on this Vistin has further increased its raw material safety stock to secure future supply and MEP ramp-up plan. Due to the increased global import from China and India leading to supply chain constraints and port congestions around the world, this has led to significantly increased freight cost (across all global businesses and for all goods). Vistin is also experiencing significant pressures from its suppliers with increasing raw materials prices, driven by higher global demand and increased raw material prices in general.

### CORPORATE SOCIAL RESPONSIBILITY

Vistin Pharma is committed to conduct its business in a manner that adheres to the highest industry standards within the pharmaceutical industry, and strictly in accordance with international and local laws and regulations. Vistin Pharma is a socially responsible company dedicated to promoting decent working and environmental conditions in the supply chains. Vistin Pharma has adopted the general principles of UN Global Compact with universally accepted principles for human rights, working conditions, environment, and anti-corruption. In pursuit of this the Group has developed a 'NO HARM VISON' consisting of:

- Vision is to have no negative impact on environment, people and local community by our presence
- Vistin is a «green» and environmentally friendly pharmaceutical company with a "no harm" vision and "front runner" ambition
- Our goal is to increase our manufacturing capacity without increased environmental impact on water, air and soil

Vistin Pharma has during the last years significantly invested in, completed and implemented several projects that significantly reduce the environmental footprint. Building on this success, Vistin Pharma has additional ESG initiatives ongoing:

- Vistin continue to use only hydro powered energy to minimize carbon footprint
- Vistin is completing a project in 2022 with aim to reduce the water consumption in the plant by >80% through recycling, incl. reusing the hot water for heating of plant. Vistin is working on a technology project where distillation will be fractionated into components that can be used as raw materials for other companies.
- Vistin has, since 2017, been part of a national program for surveillance of industrial impact on fjords and effluents. Surveillance program and ecotoxicology test confirm that Vistin do not impact the effluent negatively.

 Vistin is currently investing MNOK 10 in a cooling system to condense hydrocarbons. This is expected to reduce the emission with more than 98%, resulting in a reduction of the total emission to air with more than 95 % compared to current level. Project is expected to be finalized in Q1'22.

### **RISKS AND UNCERTAINTIES**

As a pharmaceutical manufacturing company, Vistin Pharma is exposed to several types of risk. Fluctuations in the price and availability of raw materials and the development in foreign exchange (USD and EUR) are among the most prominent. Majority of the sales are done in EUR, while all primary raw material purchases are in USD. In addition, risk related to potential regulatory changes, new medications for the treatment of diabetes II, and environmental issues connected to emission permits at the Company's plant, represent central risk factors to the Company.

#### **BASIS OF PRESENTATION**

This financial information should be read together with the financial statements for the year ended 31 December 2020, prepared in accordance with International Financial Reporting Standards ("IFRS"). The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Additional disclosures supplementing the financial statements are included in this report on pages 2-5. The figures are unaudited.

#### EVENTS AFTER THE REPORTING DATE

There have not been events after the reporting date that affect the Company's financials.

#### **GENERAL MARKET OUTLOOK**


Diabetes is one of the largest global health crises of the 21st century, and the metformin business is expected to continue to grow by 5-6% annually, as it remains the gold-standard treatment of type 2 diabetes. The majority of Vistin Pharma's key customers are pharmaceutical companies that sell new and innovative metformin products, and the demand for the Company's metformin will be dependent on the market performance of these products.

The demand in the market for metformin is still high and is currently not affected by the corona epidemic. The vulnerability for drug supplies during the corona epidemic has been an 'eye opener' for the authorities and the need for 'short travelled medicines' will be high on the agenda going forward. Vistin is strategically well positioned to benefit from the expected increase in local supplies going forward.

#### SHAREHOLDER INFORMATION

The Company had 44 344 592 issued shares as of 31 December 2021. The five largest shareholders were Intertrade Shipping AS with 12,575,000 shares, Pactum AS with 3,519,733 shares, Holmen Spesialfond with 3,250,000 shares, MP Pensjon PK with 1,719,848 shares, and Tigerstaden AS with 850,000 shares.

The share price has moved from NOK 19.8 per share at 30 of September, and to NOK 19.4 as of 31 December 2021, equal to a decrease of 2%. Vistin paid dividend of NOK 0.5 per share in June.



# VISTIN PHARMA ASA - FOURTH QUARTER REPORT 2021

	QTR	QTR	YTD	YTD
Condensed financial statement (P&L)	4. quarter 2021	4. quarter 2020	31.12.2021	31.12.2020
All numbers in NOK 1000				
Total revenue and income	78 119	64 421	278 623	253 905
Cost of materials	24 996	14 740	96 097	73 288
Salary and sosial expenses	21 875	19 868	73 426	72 499
Other operating expenses	19 923	16 606	65 241	52 940
Total operating expenses	66 795	51 214	234 765	198 728
Opr. res.before. depr. and write offs (EBITDA)	11 324	13 207	43 858	55 177
Opr.res before depr and write off %	14,5 %	20,5 %	15,7 %	21,7 %
Depreciation	2 087	2 371	10 609	9 623
Operating result	9 238	10 837	33 249	45 554
Operating result in %	11,8 %	16,8 %	11,9 %	17,9 %
Financial income	2 195	1 525	8 351	14 066
Financial expenses	2 257	1 278	9 606	183 893
Net finance	-61	247	-1 255	-169 827
Pre tax profit	9 177	11 084	31 994	-124 273
Тах	2 019	2 438	7 039	-27 351
Result	7 158	8 645	24 956	-96 922
Comprehensive income				
Result after tax	7 158	8 645	24 956	-96 922
Other comrehensive income	605	277	605	277
Total comprehensive income	7 763	8 922	25 561	-96 645
Dividend	-	_	22 172	44 345

Key figures	4. quarter 2021	4. quarter 2020	31.12.2021	31.12.2020
Equity share	83 %	85 %	83 %	85 %
Earnings per share	0,16	0,19	0,56	-2,19
Earnings per share diluted	0,16	0,19	0,56	-2,19
Average shares outstanding in 1000	44 345	44 345	44 345	44 345
Average shares outstanding in 1000 diluted	44 345	44 345	44 345	44 345

# VISTIN PHARMA ASA - FOURTH QUARTER REPORT 2021

All numbers in NOK 1000   Assets   Fixed assets 167 457   Deferred tax assets 27 890   Total tangible and fixed assets 195 348   Inventory 42 907   Trade receivables 40 245   Other receivables 40 245   Cash 35 746   Total current assets 137 799   Total assets 333 147   Share capital 44 345   Share capital 44 345   Share capital 44 345   Share premium reserve 206 885   Retained earnings 24 657   Total equity 275 887 22   Pension liabilities 15 831 2   Lease obligations 0ther non-current liabilities 512   Total long term liabilities 16 343 2   Total short term liabilities 40 916 3   Total equity and liability 333 147 33   Net interest bearing debt - -   Change in equity 31.12.2021 31.12.22   All numbers in NOK 1000 25 047 -   S	2020	31.12.2020	31.12.2021	Condensed financial statement (balance sheet)
Fixed assets 167 457 1   Deferred tax assets 27 890 1   Total tangible and fixed assets 195 348 11   Inventory 42 907 1   Trade receivables 40 245 1   Other receivables 18 901 1   Cash 35 746 1   Total assets 333 147 31   Equity and liability Share capital 44 345 4   Share capital 44 345 4 4   Share premium reserve 206 885 22 22   Pension liabilities 15 831 2 2   Total equity 275 887 22 2   Pension liabilities 15 831 2 2   Total long term liabilities 16 343 3 3   Total equity and liability 333 147 33 3   Total short term liabilities 16 343 3 3   Total equity and liability 333 147 3 3   Net interest bearing debt - - -   Change in equity 31.12.2021 <th></th> <th></th> <th></th> <th></th>				
Deferred tax assets   27 890   3     Total tangible and fixed assets   195 348   14     Inventory   42 907   3     Trade receivables   40 245   3     Other receivables   18 901   3     Cash   35 746   3     Total current assets   137 799   14     Total assets   333 147   33     Equity and liability   Share capital   44 345   4     Share premium reserve   206 885   22   Retained earnings   24 657   2     Pension liabilities   15 831   5   14   5   14     Lease obligations   016   343   15   15   15     Ottal long term liabilities   16 343   15   15   15   15     Total short term liabilities   31.12.2021   31.12.20   31.12.20   31.12.20     All numbers in NOK 1000 Equity start of period   25 047   24   16   16     Result for the period   25 047   24   16   12.2021				Assets
Total tangible and fixed assets195 348141Inventory42 9071Trade receivables40 2451Other receivables18 901Cash35 7461Total current assets137 7991Total assets333 1473Equity and liability5Share capital44 3451Share premium reserve206 8852Retained earnings24 657Total equity275 8872Pension liabilites15 8311Lease obligations512Other non-current liabilities512Total equity and liability333 1473Net interest bearing debt-Change in equity31.12.202131.12.2All numbers in NOK 1000 Equity start of period272 4054Result for the period25 047-Other comprehensive income6055Share based paymentsDividend-22 172-Equity end of period31 994-11Depreciations10 609-Working capital changes-15 594-Cash flow from operation27 009-Purchase of equipment and intangibles-38 554-Otal dual (and finance activities)-29 745-	45 261	145 2	167 457	Fixed assets
Inventory42 907Trade receivables40 245Other receivables18 901Cash35 746Total current assets137 799Total assets333 147Share capital44 345Share capital44 345Share premium reserve206 885Retained earnings24 657Total long term liabilities15 831Lease obligations512Other non-current liabilities512Total equity and liability333 147Stare premium reserve206 885Charge in equity275 887Z22Pension liabilities15 831Lease obligations512Other non-current liabilities512Total long term liabilities16 343Total short term liabilities40 916Z21All numbers in NOK 1000 Equity start of period272 405Pare based payments-Dividend-22 172Cash flow analysis YTD31.12.2021All numbers in NOK 1000275 887Result for the period31 994Cash flow analysis YTD31.12.2021All numbers in NOK 1000277 009Result for the period31 994Other compretensive income605Share based payments-Dividend275 887Cash flow from operation27 009Purchase of equipment and intangibles-38 554Other on peration27 009Purchase of equipment and intangibles-38 5	35 128	35	27 890	
Trade receivables 40 245 3   Other receivables 18 901 3   Cash 35 746 3   Total current assets 137 799 14   Total assets 333 147 3   Equity and liability 3 3   Equity and liability 5 3   Share capital 44 345 4   Share premium reserve 206 885 22   Retained earnings 24 657 2   Total equity 275 887 2   Pension liabilities 15 831 3   Lease obligations 512 512   Other non-current liabilities 512 512   Total long term liabilities 16 343 3   Total short term liabilities 40 916 3   Total equity and liability 333 147 3   Net interest bearing debt - -   Change in equity 31.12.2021 31.12.20   All numbers in NOK 1000 Equity start of period 25 047 -   Share based payments - - -   Dividend <t< td=""><td>80 389</td><td>180 :</td><td>195 348</td><td>Total tangible and fixed assets</td></t<>	80 389	180 :	195 348	Total tangible and fixed assets
Other receivables   18 901     Cash   35 746     Total current assets   137 799     Total assets   333 147     Share capital   44 345     Share capital   44 345     Share capital   44 345     Share capital   44 345     Share premium reserve   206 885     Retained earnings   24 657     Total equity   275 887     Pension liabilities   15 831     Lease obligations   0ther non-current liabilities     Other non-current liabilities   16 343     Total equity and liability   333 147     Net interest bearing debt   -     Change in equity   31.12.2021   31.12.2     All numbers in NOK 1000 Equity start of period   272 405   4     Result for the period   25 047   -     Other comprehensive income   605   5     Share based payments   -   -     Dividend   -22 172   -     Equity end of period   31 994   -12     Qall numbers in NOK 1000	31 788	31	42 907	Inventory
Cash35 746Total current assets137 799Total assets333 147Share capital44 345Share capital44 345Share premium reserve206 885Retained earnings24 657Total equity275 887Pension liabilities15 831Lease obligations512Other non-current liabilities512Total short term liabilities16 343Total short term liabilities40 916Total equity and liability333 147Stitumers in NOK 1000 Equity start of period272 405Equity start of period272 405Change in equity31.12.2021All numbers in NOK 1000 Equity start of period272 405Change in equity end of period272 405Change in equity start of period272 887Cash flow analysis YTD31.12.2021All numbers in NOK 1000Result for the period31.994Other comprehensive income605Share based payments-Dividend-22 172Cash flow analysis YTD31.12.2021All numbers in NOK 1000Result for the period31 994Operications10 609Working capital changes-15 594Cash flow from operation-27 009Out chase of equipment and intangibles-38 554Obvidend paid (and finance activities)-29 745	30 400	30 4	40 245	Trade receivables
Total current assets137 79914Total assets333 14733Equity and liabilityShare capital44 34533Share capital44 34534533Share premium reserve206 88522Retained earnings24 65727Total equity275 88727Pension liabilities15 83131Lease obligations51231Other non-current liabilities51231Total short term liabilities16 34331Total short term liabilities33 14733Net interest bearing debtChange in equity31.12.202131.12.20All numbers in NOK 1000 Equity start of period272 40544Result for the period25 047-3Other comprehensive income605-Share based paymentsDividend-22 172-Equity end of period31.12.202131.12.2021All numbers in NOK 1000Result for the period31 994-11Dividend-22 172-Cash flow analysis YTD31.12.202131.12.2021All numbers in NOK 1000-Result for the period31 994Opereciations10 609Working capital changes-15 594Cash flow from operation27 009Purchase of equipment and intangibles-38 554Oividend paid (and finance activities)-29 745	2 302			
Total assets333 147Total assets333 147Equity and liabilityShare capital44 345Share premium reserve206 885Retained earnings24 657Total equity275 887Pension liabilites15 831Lease obligations512Other non-current liabilities512Total equity and liabilities16 343Total equity and liabilities16 343Total equity and liabilities333 147Total equity and liabilities31.12.2021All numbers in NOK 1000 Equity start of period272 405Equity start of period25 047All numbers in NOK 1000 Equity start of period25 047Equity end of period25 047Change in equity31.12.2021All numbers in NOK 1000 Equity start of period275 887Equity end of period275 887Cash flow analysis YTD31.12.2021All numbers in NOK 100031 994Result for the period31 994Other comprehensive income605Share based payments-Dividend-22 172Cash flow analysis YTD31.12.2021All numbers in NOK 100031 994Result for the period31 994Cash flow from operation27 009Purchase of equipment and intangibles-38 554Cash flow from investments-38 554Dividend paid (and finance activities)-29 745	77 036			
Equity and liabilityShare capital44 345Share premium reserve206 885Retained earnings24 657Total equity275 887Pension liabilites15 831Lease obligations512Other non-current liabilities16 343Total equity and liabilities16 343Total equity and liabilities16 343Total short term liabilities40 916Total equity and liability333 147Net interest bearing debt-Change in equity31.12.2021All numbers in NOK 1000 Equity start of period272 405Equity start of period272 405Share based payments-Dividend-22 172Cash flow analysis YTD31.12.2021All numbers in NOK 1000Result for the period31 994Cash flow analysis YTD31.12.201All numbers in NOK 1000Result for the period31 994Cash flow analysis YTD31.12.201All numbers in NOK 1000Result for the period31 994Cash flow from operation27 009Purchase of equipment and intangibles-38 554Cash flow from operation-38 554Other op add (and finance activities)-29 745	41 526	141 :	137 799	lotal current assets
Share capital44 345Share premium reserve206 88522Retained earnings24 6572Total equity275 88722Pension liabilities15 8312Lease obligations512512Other non-current liabilities16 3432Total short term liabilities16 3432Total equity and liability333 1473Net interest bearing debt-31.12.2021All numbers in NOK 1000 Equity start of period272 4054Result for the period272 4054Result for the period25 047-Other comprehensive income6055Share based paymentsDividend-22 172-Equity end of period31 994-12All numbers in NOK 1000Result for the period31 994-12Dividend-22 172-Equity end of period31 994-12Depreciations10 609-Working capital changes-15 594-Cash flow from operation27 009-14Purchase of equipment and intangibles-38 554-Cash flow from investments-38 554-4Dividend paid (and finance activities)-29 745-	821 916	321 9	333 147	Total assets
Share premium reserve206 88522Retained earnings24 657Total equity275 88727Pension liabilites15 8317Lease obligations0ther non-current liabilities512Total long term liabilities16 3437Total short term liabilities40 9167Total equity and liability333 14737Net interest bearing debt-7Change in equity31.12.202131.12.2All numbers in NOK 1000 Equity start of period272 4054Equity start of period272 4054Result for the period25 047-Other comprehensive income6055Share based paymentsDividend-22 172-Equity end of period31 994-11Depreciations10 609-Working capital changes-15 594-Cash flow from operation27 009-14Purchase of equipment and intangibles-38 554-Dividend paid (and finance activities)-29 745-				Equity and liability
Retained earnings24 657Total equity275 88727Pension liabilities15 8311Lease obligations5121Other non-current liabilities16 3431Total long term liabilities16 3431Total short term liabilities40 9161Total equity and liability333 1473Net interest bearing debt-11.12.2021All numbers in NOK 1000 Equity start of period272 405Equity start of period272 405All numbers in NOK 1000 Equity start of period25 047Change in equity31.12.2021All numbers in NOK 1000 Equity start of period275 887Equity end of period275 887Cash flow analysis YTD31.12.2021All numbers in NOK 100031 994Result for the period31 994Other comprehensive income605Share based payments-Dividend-22 172	44 345	44 3	44 345	Share capital
Total equity275 88722Pension liabilites15 8311Lease obligations5121Other non-current liabilities16 3431Total long term liabilities16 3431Total short term liabilities40 9161Total equity and liability333 14733Net interest bearing debt-1Change in equity31.12.202131.12.2All numbers in NOK 1000 Equity start of period272 4054Equity start of period272 4054Result for the period25 047-Share based paymentsDividend-22 172-Equity end of period31.12.202131.12.2021All numbers in NOK 100031 994-13Dividend31 994-13Depreciations10 609-Working capital changes-15 594-3Cash flow from operation27 009-14Purchase of equipment and intangibles-38 554-4Dividend paid (and finance activities)-29 745-4	229 056	-		
Pension liabilities15 831Lease obligationsOther non-current liabilities512Total long term liabilities16 34316 343Total short term liabilities40 91631Total equity and liability333 14733Net interest bearing debtChange in equity31.12.202131.12.2All numbers in NOK 1000 Equity start of period272 40544Result for the period25 047-Chare based paymentsDividend-22 172-Equity end of period275 88721Cash flow analysis YTD31.12.202131.12.2All numbers in NOK 1000Result for the periodCash flow analysis YTD31.12.202131.12.2All numbers in NOK 1000Result for the period31 994-11Depreciations10 609-Working capital changes-15 594-Cash flow from operation27 009-14Purchase of equipment and intangibles-38 554-Dividend paid (and finance activities)-29 745-	-996			
Lease obligationsOther non-current liabilities512Total long term liabilities16 343Total short term liabilities40 916Total equity and liability333 147Net interest bearing debt-Change in equity31.12.2021All numbers in NOK 1000 Equity start of periodEquity start of period272 405All numbers in NOK 1000 Equity start of periodChange in equity21.12.2021All numbers in NOK 1000 Equity start of periodEquity start of period272 405Change based payments-Dividend-22 172Cash flow analysis YTD31.12.2021All numbers in NOK 1000Result for the period31 994Cash flow analysis YTD31.994All numbers in NOK 1000Result for the period31 994Cash flow analysis YTD31.994All numbers in NOK 1000Result for the period31 994Purchase of equipment and intangibles-38 554Other from investments-38 554Dividend paid (and finance activities)-29 745	272 405	272	275 887	l otal equity
Total long term liabilities16 343Total short term liabilities40 916Total equity and liability333 147Net interest bearing debt-Change in equity31.12.2021All numbers in NOK 1000 Equity start of period272 405Equity start of period272 405All numbers in NOK 1000 Equity start of period272 405Equity start of period25 047Change in equity31.12.2021All numbers in NOK 1000 Equity start of period272 405Equity start of period272 405Cash flow analysis YTD31.12.2021All numbers in NOK 100031.994Result for the period31.994Cash flow analysis YTD31.994Opereciations10 609Working capital changes-15 594Cash flow from operation27 009Purchase of equipment and intangibles-38 554Dividend paid (and finance activities)-29 745	16 330	163	15 831	
Total short term liabilities40 916Total equity and liability333 147Net interest bearing debt-Change in equity31.12.2021All numbers in NOK 1000 Equity start of periodEquity start of period272 405All numbers in NOK 1000 Equity start of periodEquity start of period25 047Change in equity31.12.2021All numbers in NOK 1000 Equity start of periodEquity start of period272 405All numbers in now605Share based payments-Dividend-22 172Equity end of period275 887Z275 887Cash flow analysis YTD31.12.2021All numbers in NOK 100031 994Result for the period31 994Depreciations10 609Working capital changes-15 594Cash flow from operation27 009Purchase of equipment and intangibles-38 554Oividend paid (and finance activities)-29 745	976	9	512	
Total equity and liability333 147Net interest bearing debt-Change in equity31.12.2021All numbers in NOK 1000 Equity start of period31.12.2021Equity start of period272 405All numbers in NOK 1000 Equity start of period272 405Equity start of period272 405All numbers in nok25 047Change in equity272 405All numbers in nok25 047Other comprehensive income605Share based payments-Dividend-22 172Equity end of period275 887Zash flow analysis YTD31.12.2021All numbers in NOK 100031 994Result for the period31 994Depreciations10 609Working capital changes-15 594Cash flow from operation27 009Purchase of equipment and intangibles-38 554Cash flow from investments-38 554Dividend paid (and finance activities)-29 745	17 306	17 :	16 343	Total long term liabilities
Net interest bearing debt-Change in equity31.12.202131.12.2All numbers in NOK 1000 Equity start of period272 4054Equity start of period272 4054Result for the period25 047-Other comprehensive income605-Share based paymentsDividend-22 172-Equity end of period275 8872Cash flow analysis YTD31.12.202131.12.2All numbers in NOK 100031 994-11Result for the period31 994-11Depreciations10 609-Working capital changes-15 594-Cash flow from operation27 009-14Purchase of equipment and intangibles-38 554-Cash flow from investments-38 554-Dividend paid (and finance activities)-29 745-	32 204	32 2	40 916	Total short term liabilities
Change in equity31.12.202131.12.2All numbers in NOK 1000 Equity start of period272 40544Equity start of period25 047-4Result for the period25 047-4Other comprehensive income605-Share based paymentsDividend-22 172Equity end of period275 88722Cash flow analysis YTD31.12.202131.12.2All numbers in NOK 100031 994-12Result for the period31 994-12Depreciations10 609-Working capital changes-15 594-2Cash flow from operation27 009-14Purchase of equipment and intangibles-38 554-4Dividend paid (and finance activities)-29 745-4	821 916	321 9	333 147	Total equity and liability
All numbers in NOK 1000 Equity start of periodEquity start of period272 4054Result for the period25 047-4Other comprehensive income605Share based payments-Dividend-22 172-4Equity end of period275 88722Cash flow analysis YTD31.12.202131.12.2All numbers in NOK 100031 994-12Result for the period31 994-12Depreciations10 609Working capital changes-15 594-2Cash flow from operation27 009-14Purchase of equipment and intangibles-38 554-4Cash flow from investments-38 554-4Dividend paid (and finance activities)-29 745-4	-		-	Net interest bearing debt
All numbers in NOK 1000 Equity start of periodEquity start of period272 4054Result for the period25 047-4Other comprehensive income605Share based payments-Dividend-22 172-4Equity end of period275 88722Cash flow analysis YTD31.12.202131.12.2All numbers in NOK 100031 994-12Result for the period31 994-12Depreciations10 609Working capital changes-15 594-2Cash flow from operation27 009-14Purchase of equipment and intangibles-38 554-4Cash flow from investments-38 554-4Dividend paid (and finance activities)-29 745-4	2020	31.12.2020	31 12 2021	Change in equity
Equity start of period272 4054Result for the period25 047-4Other comprehensive income605-Share based paymentsDividend-22 172Equity end of period275 88727Cash flow analysis YTD31.12.202131.12.2All numbers in NOK 100031 994-11Result for the period31 994-11Depreciations10 609-Working capital changes-15 594-Cash flow from operation27 009-14Purchase of equipment and intangibles-38 554-Cash flow from investments-38 554-Dividend paid (and finance activities)-29 745-		OTTELECE		
Result for the period25 047-4Other comprehensive income605Share based payments-Dividend-22 172Equity end of period275 887Cash flow analysis YTD31.12.2021All numbers in NOK 100031 994Result for the period31 994Depreciations10 609Working capital changes-15 594Cash flow from operation27 009Purchase of equipment and intangibles-38 554Cash flow from investments-38 554Dividend paid (and finance activities)-29 745				
Other comprehensive income605Share based payments-Dividend-22 172Equity end of period275 887Cash flow analysis YTD31.12.2021All numbers in NOK 100031 994Result for the period31 994Depreciations10 609Working capital changes-15 594Cash flow from operation27 009Purchase of equipment and intangibles-38 554Cash flow from investments-38 554Dividend paid (and finance activities)-29 745	13 396	413 '		All numbers in NOK 1000 Equity start of period
Share based payments-Dividend-22 172Equity end of period275 887Cash flow analysis YTD31.12.2021All numbers in NOK 1000Result for the period31 994Pereciations10 609Working capital changes-15 594Cash flow from operation27 009Purchase of equipment and intangibles-38 554Cash flow from investments-38 554Dividend paid (and finance activities)-29 745	13 396 -96 922		272 405	All numbers in NOK 1000 Equity start of period Equity start of period
Equity end of period275 88727Cash flow analysis YTD31.12.202131.12.2All numbers in NOK 100031 994-12Result for the period31 994-12Depreciations10 609Working capital changes-15 594-2Cash flow from operation27 009-14Purchase of equipment and intangibles-38 554-4Cash flow from investments-38 554-4Dividend paid (and finance activities)-29 745-4	-96 922	-96 9	272 405 25 047	All numbers in NOK 1000 Equity start of period <b>Equity start of period</b> Result for the period
Cash flow analysis YTD31.12.202131.12.2All numbers in NOK 100031 994-12Result for the period31 994-12Depreciations10 6090Working capital changes-15 594-2Cash flow from operation27 009-14Purchase of equipment and intangibles-38 554-4Cash flow from investments-38 554-4Dividend paid (and finance activities)-29 745-4		-96 9	272 405 25 047	All numbers in NOK 1000 Equity start of period <b>Equity start of period</b> Result for the period Other comprehensive income
All numbers in NOK 1000Result for the period31 994Depreciations10 609Working capital changes-15 594 <b>Cash flow from operation27 009</b> Purchase of equipment and intangibles-38 554 <b>Cash flow from investments</b> -38 554Dividend paid (and finance activities)-29 745	-96 922	-96 9	272 405 25 047 605	All numbers in NOK 1000 Equity start of period <b>Equity start of period</b> Result for the period Other comprehensive income Share based payments
All numbers in NOK 1000Result for the period31 994Depreciations10 609Working capital changes-15 594 <b>Cash flow from operation27 009</b> Purchase of equipment and intangibles-38 554 <b>Cash flow from investments</b> -38 554Dividend paid (and finance activities)-29 745	96 922- 277 -	-96 s -44 :	272 405 25 047 605 - -22 172	All numbers in NOK 1000 Equity start of period <b>Equity start of period</b> Result for the period Other comprehensive income Share based payments Dividend
Depreciations10 609Working capital changes-15 594Cash flow from operation27 009Purchase of equipment and intangibles-38 554Cash flow from investments-38 554Dividend paid (and finance activities)-29 745	-96 922 277 - -44 345 2 <b>72 405</b>	-96 s -44 :	272 405 25 047 605 - -22 172 275 887	All numbers in NOK 1000 Equity start of period <b>Equity start of period</b> Result for the period Other comprehensive income Share based payments Dividend <b>Equity end of period</b>
Depreciations10 609Working capital changes-15 594Cash flow from operation27 009Purchase of equipment and intangibles-38 554Cash flow from investments-38 554Dividend paid (and finance activities)-29 745	-96 922 277 - -44 345 2 <b>72 405</b>	-96 9 -44 3 <b>272</b> 4	272 405 25 047 605 - -22 172 275 887	All numbers in NOK 1000 Equity start of period <b>Equity start of period</b> Result for the period Other comprehensive income Share based payments Dividend <b>Equity end of period</b> <b>Cash flow analysis YTD</b>
Working capital changes-15 594Cash flow from operation27 009-14Purchase of equipment and intangibles38 554Cash flow from investments38 554Dividend paid (and finance activities)-29 745	-96 922 277 - -44 345 2 <b>72 405</b>	-96 9 -44 3 272 4 31.12.2020	272 405 25 047 605 - -22 172 275 887 31.12.2021	All numbers in NOK 1000 Equity start of period Equity start of period Result for the period Other comprehensive income Share based payments Dividend Equity end of period Cash flow analysis YTD All numbers in NOK 1000
Purchase of equipment and intangibles-38 554-38Cash flow from investments-38 554-38Dividend paid (and finance activities)-29 745-40	-96 922 277 - -44 345 272 405 2020	-96 9 -44 2 272 4 31.12.2020 -124 2	272 405 25 047 605 - -22 172 <b>275 887</b> <b>31.12.2021</b> 31 994	All numbers in NOK 1000 Equity start of period Equity start of period Result for the period Other comprehensive income Share based payments Dividend Equity end of period Cash flow analysis YTD All numbers in NOK 1000 Result for the period
Cash flow from investments-38 554-4Dividend paid (and finance activities)-29 745-4	-96 922 277 - -44 345 <b>272 405</b> 2020	-96 9 -44 3 272 4 31.12.2020 -124 2 9 0	272 405 25 047 605 -22 172 <b>275 887</b> <b>31.12.2021</b> 31 994 10 609	All numbers in NOK 1000 Equity start of period Equity start of period Result for the period Other comprehensive income Share based payments Dividend Equity end of period Cash flow analysis YTD All numbers in NOK 1000 Result for the period Depreciations
	-96 922 277 - 44 345 272 405 2020 24 273 9 623	-96 9 -44 3 272 4 31.12.2020 -124 2 9 0 -30 2	272 405 25 047 605 - -22 172 <b>275 887</b> <b>31.12.2021</b> 31 994 10 609 -15 594	All numbers in NOK 1000 Equity start of period Equity start of period Result for the period Other comprehensive income Share based payments Dividend Equity end of period Cash flow analysis YTD All numbers in NOK 1000 Result for the period Depreciations Working capital changes
	-96 922 277 -44 345 272 405 2020 24 273 9 623 -30 209	-96 9 -44 2 272 4 31.12.2020 -124 2 9 0 -30 2 -144 8 -51 9	272 405 25 047 605 -22 172 <b>275 887</b> <b>31.12.2021</b> 31 994 10 609 -15 594 <b>27 009</b> -38 554	All numbers in NOK 1000 Equity start of period Equity start of period Result for the period Other comprehensive income Share based payments Dividend Equity end of period Cash flow analysis YTD All numbers in NOK 1000 Result for the period Depreciations Working capital changes Cash flow from operation Purchase of equipment and intangibles
Change in cash for the period -41 290 -24	-96 922 277 -44 345 272 405 2020 24 273 9 623 -30 209 44 859 -51 982	-96 9 -44 3 272 4 31.12.2020 -124 3 9 0 -30 2 -144 9 -51 9 -51 9 -51 9 -51 9	272 405 25 047 605 - 22 172 <b>275 887</b> <b>31.12.2021</b> 31 994 10 609 -15 594 <b>27 009</b> -38 554 <b>-38 554</b> <b>-38 554</b> -29 745	All numbers in NOK 1000 Equity start of period Equity start of period Result for the period Other comprehensive income Share based payments Dividend Equity end of period Cash flow analysis YTD All numbers in NOK 1000 Result for the period Depreciations Working capital changes Cash flow from operation Purchase of equipment and intangibles Cash flow from investments Dividend paid (and finance activities)
Cash at start of period 77 036 3	-96 922 277 -44 345 272 405 2020 242 273 9 623 -30 209 44 859 -51 982 -51 982 -51 982	-96 9 -44 3 272 4 31.12.2020 -124 3 9 0 -30 3 -144 9 -51 9 -51 9 -51 9 -44 3 -45 3	272 405 25 047 605 -22 172 275 887 31.12.2021 31 994 10 609 -15 594 27 009 -38 554 -38 554 -29 745 -29 745 -29 745	All numbers in NOK 1000 Equity start of period Equity start of period Result for the period Other comprehensive income Share based payments Dividend Equity end of period Cash flow analysis YTD All numbers in NOK 1000 Result for the period Depreciations Working capital changes Cash flow from operation Purchase of equipment and intangibles Cash flow from investments Dividend paid (and finance activities) Cash flow finance activities
Cash by the end of period 35 746	-96 922 277 -44 345 272 405 2020 24 273 9 623 -30 209 44 859 -51 982 -51 982 -51 982 -51 982 -51 982 -51 982 -51 982	-96 9 -44 2 272 4 31.12.2020 -124 2 9 0 -30 2 -30 2 -144 8 -51 9 -51 9 -51 9 -51 9 -51 9 -44 2 -51 9 -44 2 -44 2 -44 2 -242 0	272 405 25 047 605 -22 172 <b>275 887</b> <b>31.12.2021</b> 31 994 10 609 -15 594 <b>27 009</b> -38 554 <b>-38 554</b> -29 745 <b>-29 745</b> <b>-29 745-29 745</b> <b>-29 745</b> <b>-29 745-29 745</b> <b>-29 745</b> <b>-29 745-29 745</b> <b>-29 745</b> <b>-29 745</b> <b>-29 745-29 745</b> <b>-29 745-29 745</b> <b>-29 745</b> <b>-29 745-29 745</b> <b>-29 745-20 745</b> <b>-29 745-21-21-21-21-21-21-21-21</b>	All numbers in NOK 1000 Equity start of period Equity start of period Result for the period Other comprehensive income Share based payments Dividend Equity end of period Cash flow analysis YTD All numbers in NOK 1000 Result for the period Depreciations Working capital changes Cash flow from operation Purchase of equipment and intangibles Cash flow from investments Dividend paid (and finance activities) Cash flow finance activities Change in cash for the period

# VISTIN PHARMA ASA - FOURTH QUARTER REPORT 2021

Segment reporting (P&L)	4. quarter 2021 4	4. quarter 2020	YTD 31.12.2021	YTD 31.12.2020
All numbers in NOK 1000				
Total revenue and income				
Pharmaceuticals	78 119	64 421	278 623	253 905
Total revenue and income	78 119	64 421	278 623	253 905
EBITDA				
Pharmaceuticals	12 151	13 922	48 556	58 189
Energy Trading	-	-51	-	-190
HQ & Other	-826	-664	-4 698	-2 822
EBITDA	11 324	13 207	43 858	55 177
EBT				
Pharmaceuticals	9 916	11 547	36 430	39 805
Energy Trading	-	-48	-	-162 117
HQ & Other	-740	-415	-4 436	-2 010
EBT	9 177	11 084	31 994	-124 323

Segment reporting (balance sheet)	31.12.2021	31.12.2020
All numbers in NOK 1000		
Operating assets		
Pharmaceuticals	267 489	207 449
Energy Trading	-	-
HQ & Other	37 767	79 338
Total segments	305 256	286 787
Operating liabilities		
Pharmaceuticals	55 620	35 577
Energy Trading	-	-
HQ & Other	1 639	17 236
Total segments	57 259	52 813
Reconciliation of assets		
Segment operating assets	305 256	286 787
Deferred tax assets	27 890	35 128
Total operating assets	333 147	321 916
Reconciliation of liabilities		
Segment operating liabilities Tax payable	57 259	52 813
Total operating liabilities	57 259	52 813